Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience. (28th March 2022)

• Record Type: Journal Article
• Authors: Macías-Sánchez, María del Mar; Morata-Tarifa, Cynthia; Cuende, Natividad; Cardesa-Gil, Ana; Cuesta-Casas, María Ángeles; Pascual-Cascon, María Jesús; Pascual, Antonia; Martín-Calvo, Carmen; Jurado, Manuel; Perez-Simón, José Antonio; Espigado, Ildefonso; Garzón López, Sebastián; Carmona Sánchez, Gloria; Mata-Alcázar-Caballero, Rosario; Sánchez-Pernaute, Rosario
• Is Part Of: Stem cells translational medicine. Volume 11:Number 4(2022)
• Page Start: 343
• Page End: 355
• Publication Date: 2022-03-28
• Subjects: mesenchymal stromal cells -- allogenic hematopoietic stem cell transplantation -- graft versus host disease -- cell therapy; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.1093/stcltm/szac003
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract: Graft versus host disease (GVHD) is a severe complication after allogenic hematopoietic cell transplantation (HSCT). Several clinical trials have reported the use of mesenchymal stromal cells (MSCs) for the treatment of GVHD. In March 2008, the Andalusian Health Care System launched a compassionate use program to treat steroid-resistant GVHD with MSC. Clinical-grade MSC were obtained under GMP conditions. MSC therapy was administered intravenously in four separate doses of 1 × 10 6 cells/kg. Sixty-two patients, 45 males (7 children) and 17 females (2 children), received the treatment. Patients had a median age of 39 years (range: 7–66) at the time of the allogenic HSCT. The overall response was achieved in 58.7% of patients with acute (a)GVHD. Two years' survival for aGVHD responders was 51.85%. The overall response for patients with chronic (c)GVHD was 65.50% and the 2-year survival rate for responders was 70%. Age at the time of HSCT was the only predictor found to be inversely correlated with survival in aGVHD. Regarding safety, four adverse events were reported, all recovered without sequelae. Thus, analysis of this compassionate use experience shows MSC to be an effective and safe therapeutic option for treating refractory GVHD, resulting in a significant proportion of patients responding to the therapy. Graphical Abstract: